Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

Highlights from the ASCO presentations will include results from the Phase 3 C-POST trial, which explores the adjuvant use of PD-1 inhibitor Libtayo in high-risk cutaneous squamous cell carcinoma ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Today at the F1 Miami Grand Prix circuit, Sir Lewis Hamilton's global foundation Mission 44 and HP Inc. (NYSE: HPQ) announced a multi-year partnership to fuel ...

Libtayo in the U.S. grew 21% compared to the first quarter of last year and has established itself as a cornerstone therapy for advanced non-melanoma skin cancer, while its share of the lung ...

Dupixent US Net Sales: $2.6 billion, up 19% year-over-year. Libtayo Global Net Sales: $285 million, up 8% year-over-year on a constant currency basis. Free Cash Flow: $816 million for Q1 2025.